Corrigendum to: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
作者信息
Steffel Jan, Collins Ronan, Antz Matthias, Cornu Pieter, Desteghe Lien, Haeusler Karl Georg, Oldgren Jonas, Reinecke Holger, Roldan-Schilling Vanessa, Rowell Nigel, Sinnaeve Peter, Vanassche Thomas, Potpara Tatjana, Camm A John, Heidbüchel Hein
出版信息
Europace. 2021 Oct 9;23(10):1676. doi: 10.1093/europace/euab157.
Abstract
摘要
相似文献
1
Corrigendum to: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
Europace. 2021 Oct 9;23(10):1676. doi: 10.1093/europace/euab157.
2
Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary.
Eur Heart J. 2017 Jul 14;38(27):2137-2149. doi: 10.1093/eurheartj/ehw058.
3
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
Eur Heart J. 2018 Apr 21;39(16):1330-1393. doi: 10.1093/eurheartj/ehy136.
4
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.
Europace. 2015 Oct;17(10):1467-507. doi: 10.1093/europace/euv309. Epub 2015 Aug 31.
5
[Recommendations on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (Based on 2018 European Heart Rhythm Association Practical Guide)].
Kardiologiia. 2019 May 25;59(5):68-79. doi: 10.18087/cardio.2019.5.2633.
6
2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: comment.
Europace. 2021 Oct 9;23(10):1685. doi: 10.1093/europace/euab217.
7
2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: comment-Authors' reply.
Europace. 2021 Oct 9;23(10):1685-1686. doi: 10.1093/europace/euab218.
8
2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.
Europace. 2021 Oct 9;23(10):1612-1676. doi: 10.1093/europace/euab065.
9
Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
Europace. 2017 Nov 1;19(11):1757-1758. doi: 10.1093/europace/eux240.
10
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary.
Europace. 2018 Aug 1;20(8):1231-1242. doi: 10.1093/europace/euy054.
引用本文的文献
1
Does the type of oral anticoagulant matter for stroke prevention or bleeding in patients with atrial fibrillation after cardiac surgery? A systematic review and meta-analysis.
Eur Heart J Open. 2025 Jun 4;5(3):oeaf062. doi: 10.1093/ehjopen/oeaf062. eCollection 2025 May.
2
Patient preferences for stroke prevention treatments in atrial fibrillation in Asia: A discrete choice experiment.
Prev Med Rep. 2025 Apr 25;54:103084. doi: 10.1016/j.pmedr.2025.103084. eCollection 2025 Jun.
3
Reduced dose direct oral anticoagulants and time-in-therapeutic-range defined warfarin in new-onset atrial fibrillation: a report from the nationwide FinACAF study.
Eur Heart J Open. 2025 Apr 23;5(3):oeaf046. doi: 10.1093/ehjopen/oeaf046. eCollection 2025 May.
4
Concomitant Drug Interactions With Non-Vitamin K Oral Anticoagulants Are Associated With Bleeding and Mortality Risk in Patients With Nonvalvular Atrial Fibrillation.
J Am Heart Assoc. 2025 May 6;14(9):e038668. doi: 10.1161/JAHA.124.038668. Epub 2025 Apr 17.
5
Outcomes and Disease Management in Patients With Atrial Fibrillation ≥80 Years: Data From a Consecutive 11-Year Real-World Registry.
J Am Heart Assoc. 2025 Feb 18;14(4):e036832. doi: 10.1161/JAHA.124.036832. Epub 2025 Feb 8.
6
"Evaluating the efficacy and safety of direct oral anticoagulants compared to warfarin in very morbidly obese patients with non-valvular atrial fibrillation: A retrospective cohort study".
Heliyon. 2025 Jan 3;11(1):e41596. doi: 10.1016/j.heliyon.2024.e41596. eCollection 2025 Jan 15.
7
Bleeding Associated With Antiarrhythmic Drugs in Patients With Atrial Fibrillation Using Direct Oral Anticoagulants: A Nationwide Population Cohort Study.
J Am Heart Assoc. 2024 Nov 5;13(21):e033513. doi: 10.1161/JAHA.123.033513. Epub 2024 Nov 4.
8
Thromboembolic prevention in athletes: management of anticoagulation in sports players affected by atrial fibrillation.
Front Pharmacol. 2024 May 10;15:1384213. doi: 10.3389/fphar.2024.1384213. eCollection 2024.
9
Impact of renal function variability on long-term prognosis in ischemic stroke patients with atrial fibrillation.
Front Neurol. 2024 Apr 22;15:1294022. doi: 10.3389/fneur.2024.1294022. eCollection 2024.
10
Appropriateness of prescribing profiles and intake adherence to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: analysis of a retrospective longitudinal study using real-world data from Northern Portugal (AF-React Study).
BMJ Open. 2024 Apr 30;14(4):e076108. doi: 10.1136/bmjopen-2023-076108.
Zotero 插件